Cannabinoids may treat UTD’s In MS Patients – From NCBI- A study published in the British Journal of Urology International was published online by the U.S. National Institute of Health.
What Is MS?
From the Multiple Sclerosis Society – Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.
The cause of MS is still unknown – scientists believe the disease is triggered by as-yet-unidentified environmental factor in a person who is genetically predisposed to respond.
The progress, severity and specific symptoms of MS in any one person cannot yet be predicted. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease.
According to researchers, the study’s objective was; “To systematically review all available evidence on efficacy and safety of cannabinoids for treating neurogenic lower urinary tract dysfunction (NLUTD) in patients with multiple sclerosis (MS).”
After screening 8469 articles, two randomized controlled trials and one open label study enrolling a total of 426 patients, were included.
“Cannabinoids relevantly decreased incontinence episodes in all three studies”, says researchers. “Pooling data showed mean difference in incontinence episodes per 24 hours to be -0.35 (95% confidence interval -0.46 to -0.24).”
The study concludes; “ Preliminary data imply, that cannabinoids might be an effective and safe treatment option for NULTD in patients with MS.”
Click here for the full text of the study.